Skip to Main Content

Intercept Pharmaceuticals, Inc. Securities Fraud Class Action

View Complaint
COMPANY         Intercept Pharmaceuticals, Inc.
COURT United States District Court for the Southern District of New York
CASE NUMBER 20-cv-00036
JUDGE The Honorable Lewis J. Liman
CLASS PERIOD September 28, 2019 - October 7, 2020
SECURITY TYPE  Common Stock

Case Background:

This action is brought on behalf of all investors who purchased Intercept Pharmaceuticals, Inc. common stock between September 27, 2019 and October 8, 2020 (the “Class Period”). 

The complaint alleges that throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) the defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve Intercept’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, Intercept’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

On March 21, 2022, the Court granted Defendants’ Motion to Dismiss the complaint.  On April 20, 2022, the Court directed the clerk to close the case. This action has concluded.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) securities between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Intercept Pharmaceuticals, Inc. (2020) prior to the Class Period?
Are you a current or former employee of Intercept Pharmaceuticals, Inc. (2020)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email